I agree, I was not expecting this at all ... pleasantly surprised and happy, all things considered.

The next few months are going to be very interesting:

1. FLD & Secondary endpoints

2. Financial disclosures (and plans)

With the fall lineup of important congresses, plus the AGM, we will get a lot of info.

Still holding my breath a bit for stability in the market (not just a blip from the "short covers" buying support?), operating capital news, and of course more BoM data disclosures. I would expect any good data news to come out in drips at appropriate congresses in order to sustain a flow of "good" news to support an ongoing structure of a "rebuild" of confidence, and also for impact and ground-swell grass roots support from within the medical/academic communities for keeping the scince developing and moving forward.

Dream scenario - FLD looks amazing for Crestor/Apabetalone, and there is a cogent argument for moving THIS combo forward despite TLD shortcomings, ... plus immense pressure from within the medical communities to move this "option" forward for the good of applicable patients, plus the potential financial benefits within the "payor systems" from slowing disease progression and MACE. And of course, exciting and compelling secondary endpoints data for pressure within those communities as well. But, an avenue to an NDA in the short term would be huge if not a pipedream at this point.

Sooooo, the current bounce? ..... 1) Short covers still at work? ... 2) Entities accumulating and seeking control, or stronger influence at bargain prices compared to the potential of the science long term? ... 3) Optimism re FLD? ... 4) General retail Optimism long term for the RVX science at a bargain again, for the truely longgggg?